Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

BACKGROUND: In recurrent malignant gliomas (MGs), a high rate of haematological toxicity is observed with the use of fotemustine at the conventional schedule (100 mg/m(2 )weekly for 3 consecutive weeks followed by triweekly administration after a 5-week rest period). Also, the impact of O6-methylgua...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabi, Alessandra, Metro, Giulio, Russillo, Michelangelo, Vidiri, Antonello, Carapella, Carmine Maria, Maschio, Marta, Cognetti, Francesco, Jandolo, Bruno, Mirri, Maria Alessandra, Sperduti, Isabella, Telera, Stefano, Carosi, Mariantonia, Pace, Andrea
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667532/
https://www.ncbi.nlm.nih.gov/pubmed/19335893
http://dx.doi.org/10.1186/1471-2407-9-101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667532/
https://www.ncbi.nlm.nih.gov/pubmed/19335893
http://dx.doi.org/10.1186/1471-2407-9-101

Ejemplares similares